| 195.0423 2.492 (1.29%) | 03-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 232.94  |
1-year : | 272.08 |
| Resists | First : | 199.44 |
Second : | 232.94 |
| Pivot price | 195.78 |
|||
| Supports | First : | 193.8 |
Second : | 190.32 |
| MAs | MA(5) : | 195.24  |
MA(20) : | 196.05 |
| MA(100) : | 189.6 |
MA(250) : | 169.87 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 48.8 |
D(3) : | 56.6 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 202.91 | Low : | 134.66 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BBH ] has closed above bottom band by 39.3%. Bollinger Bands are 39.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 196.35 - 197.44 | 197.44 - 198.45 |
| Low: | 189.02 - 190.47 | 190.47 - 191.8 |
| Close: | 192.94 - 195.04 | 195.04 - 196.97 |
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Fri, 13 Feb 2026
BBH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Wed, 11 Feb 2026
7 Best Biotech ETFs to Buy Now | Investing - Money/ US News
Wed, 21 Jan 2026
BBH: Mature Biotech Exposure, But Limited Growth Ahead (NASDAQ:BBH) - Seeking Alpha
Tue, 06 Jan 2026
Should You Invest in the VanEck Biotech ETF (BBH)? - Yahoo Finance
Wed, 03 Dec 2025
AI in Pharma and Biotech: Market Trends 2025 and Beyond - VanEck
Mon, 13 Oct 2025
VanEck Biotech ETF (NASDAQ:BBH) - intelligentinvestor.com.au
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|